<p><strong>🎤Kelly Broster McMahon (Senior Manager of Market Development and Collaborations at Thermo Fisher Scientific).&nbsp;</strong></p><p>Kelly has over 15 years of experience in LC-MS and protein mass spectrometry. Her work focuses on translating complex analytical challenges into scalable, compliant workflows for the biopharmaceutical industry.</p><p><strong>In this episode of Concentrating on Chromatography, we sit down with Kelly Broster McMahon to explore the analytical science behind one of the most important pharmaceutical trends today: GLP-1 therapeutics.</strong></p><p>Drugs like Semaglutide have transformed the treatment of diabetes and obesity—but ensuring their safety, efficacy, and quality requires cutting-edge analytical workflows.</p><p>In this conversation, we break down how chromatography and high-resolution mass spectrometry (LC-MS) work together to characterize complex peptide therapeutics, detect trace-level impurities, and support drug development from early research through regulated manufacturing.</p><h4><strong>What You’ll Learn</strong></h4><ul><li>Why GLP-1 drugs are uniquely challenging to analyze</li><li>How LC-MS enables detailed peptide characterization</li><li>The importance of detecting low-level impurities for patient safety</li><li>How analytical workflows scale from R&amp;D to manufacturing</li><li>The role of software and data platforms in modern labs</li><li>Where chromatography and mass spectrometry are heading next</li></ul><h4><strong>Key Takeaways</strong></h4><ul><li>GLP-1 therapeutics are a “proof point” for the future of analytical chemistry—where success depends not on measuring more, but on measuring the right things earlier, with confidence.</li><li>As molecules become more complex, integrated workflows combining chromatography, high-resolution mass spectrometry, and advanced informatics are becoming essential to ensure data integrity, regulatory compliance, and ultimately, patient safety.</li></ul><h3><strong>Video Transcription</strong></h3><p>In this episode, Kelly, Senior Manager of Market Development and Collaborations at Thermo Fisher Scientific, discusses the analytical challenges associated with GLP-1 peptide therapeutics and explains how modern chromatography, high-resolution mass spectrometry, software, and data platforms are shaping the future of biopharmaceutical development. Drawing on more than 15 years of experience in LC-MS and protein mass spectrometry, she shares insights into peptide characterization, impurity profiling, workflow continuity, and the growing role of AI in analytical science.</p><h4><strong>Kelly's Background in Biopharmaceutical Analysis</strong></h4><p>Kelly currently focuses on biopharmaceutical development at Thermo Fisher Scientific, working closely with industry partners to transform complex analytical challenges into scalable and compliant workflows. Her scientific background includes cancer biology, quantitative proteomics, biomarker assays, systems oncology, and mass spectrometry-based drug discovery. Throughout her academic and industrial career, she has applied mass spectrometry to support patient stratification, treatment monitoring, and therapeutic development.</p><h4><strong>Why GLP-1 Therapeutics Are So Important Right Now</strong></h4><p>GLP-1 drugs have become one of the most discussed therapeutic classes because they occupy a unique space between traditional small molecules and large biologics. Their structural complexity, sensitivity to degradation, and global manufacturing scale make them an ideal example of how analytical science must evolve.</p><p>According to Kelly, these molecules require greater analytical sensitivity, deeper structural characterization, and seamless workflows that support everything from discovery through manufacturing and regulatory submission.</p><h4><strong>Analytical Challenges of Peptide Therapeutics</strong></h4><p>Unlike conventional small molecules, peptide drugs such as semaglutide are larger, conformationally dynamic, and often chemically modified to improve stability, half-life, and absorption.</p><p>These therapeutics may contain:</p><ul><li>Sequence variants</li><li>Oxidation products</li><li>Deamidation products</li><li>Aggregates</li><li>Trace-level impurities</li></ul><p>Many of these species are difficult to separate chromatographically and challenging to identify confidently. As a result, peptide characterization requires both highly selective chromatography and high-resolution accurate-mass spectrometry.</p><h4><strong>What GLP-1 Drugs Teach Us About the Future of Analytical Science</strong></h4><p>Kelly emphasized that the future of analytical science is not necessarily about generating more data but about measuring the right attributes earlier and with greater confidence.</p><p>GLP-1 developers increasingly require integrated analytical workflows that generate actionable insights during discovery while remaining robust enough to support late-stage development, manufacturing, and global regulatory filings. This trend highlights the growing importance of scalable and harmonized analytical ecosystems.</p><h4><strong>Why Small Molecular Changes Matter</strong></h4><p>Even a single amino acid substitution or post-translational modification can dramatically alter a peptide's biological behavior.</p><p>Minor structural changes may affect:</p><ul><li>Receptor binding</li><li>Potency</li><li>Stability</li><li>Immunogenicity</li></ul><p>Because these changes can directly influence safety and efficacy, regulatory agencies require precise structural characterization and control throughout development and manufacturing.</p><h4><strong>The Power of Combining Chromatography and Mass Spectrometry</strong></h4><p>For complex peptide therapeutics, chromatography and mass spectrometry work together to provide comprehensive characterization.</p><p>Chromatography separates complex mixtures and resolves closely related species, while high-resolution mass spectrometry provides molecular specificity and structural confirmation. Together, advanced UHPLC and HRAM MS deliver the selectivity, sensitivity, and confidence required for modern peptide analysis.</p><h4><strong>The Value of High-Resolution Accurate-Mass Spectrometry</strong></h4><p>Kelly described high-resolution accurate-mass (HRAM) mass spectrometry as an indispensable technology for drug development.</p><p>Compared with older analytical approaches, HRAM provides:</p><ul><li>Exact mass measurements</li><li>Isotopic resolution</li><li>Structural confirmation</li><li>Trace impurity detection</li><li>Identification of sequence variants</li><li>Characterization of post-translational modifications</li></ul><p>These capabilities enable confident data generation that can withstand regulatory scrutiny, audits, and global submissions.</p><h4><strong>Why Sensitivity Is Critical</strong></h4><p>The distinction between a safe and unsafe therapeutic can exist at extremely low concentration levels.</p><p>Detecting impurities at parts-per-billion levels allows developers to identify risks early in development and address them before manufacturing scale-up. Analytical sensitivity therefore supports both regulatory confidence and patient safety.</p><h4><strong>Resolving Co-Eluting Impurities</strong></h4><p>One of the greatest challenges in peptide analysis is distinguishing nearly identical molecular species.</p><p>By combining ultra-high-resolution mass spectrometry with optimized chromatographic separations, scientists can accurately differentiate closely related compounds and remove uncertainty from impurity profiling. This capability is essential for both regulatory submissions and therapeutic safety assessments.</p><h4><strong>Workflow Continuity Across Drug Development</strong></h4><p>Kelly stressed that analytical methods should not be reinvented at every stage of development.</p><p>Instead, workflows should transition smoothly from:</p><ul><li>Research and discovery</li><li>Development</li><li>Quality control</li><li>Manufacturing</li></ul><p>Maintaining continuity improves reproducibility, preserves data integrity, and enables scalable development without disrupting analytical performance.</p><h4><strong>The Evolution of Instruments, Software, and Data Platforms</strong></h4><p>Modern analytical ecosystems extend beyond LC-MS instrumentation alone.</p><p>Today's workflows integrate:</p><ul><li>Consumables</li><li>Chromatography systems</li><li>Mass spectrometers</li><li>Informatics platforms</li></ul><p>Instrumentation continues to become faster, more sensitive, and capable of higher throughput, while advanced software transforms complex datasets into actionable insights. These integrated platforms support compliance, traceability, and harmonized global operations.</p><h4><strong>Data Integrity and Regulatory Compliance</strong></h4><p>As drug development becomes increasingly global, maintaining data integrity is more important than ever.</p><p>Validated software systems, secure data management tools, and comprehensive audit trails help organizations harmonize workflows across multiple sites while ensuring that generated data can withstand regulatory review worldwide.</p><h4><strong>Lessons for Next-Generation Biologics</strong></h4><p>Although GLP-1 therapeutics are currently in the spotlight, Kelly believes the broader lesson is that molecular complexity is increasing across all therapeutic classes.</p><p>This includes:</p><ul><li>Peptides</li><li>Monoclonal antibodies</li><li>Fusion proteins</li><li>Advanced biologics</li></ul><p>Across all these modalities, the need for deeper molecular understanding, early risk detection, and scalable analytical control continues to grow.</p><h4><strong>Biosimilars, Generics, and Equivalence Testing</strong></h4><p>As GLP-1 patents expire, analytical science will play a crucial role in establishing biosimilarity and equivalence.</p><p>Developers must demonstrate rigorous structural and functional comparability between original products and follow-on versions. High-resolution analytical platforms provide the depth of characterization required to prove equivalence while protecting patient safety and therapeutic efficacy.</p><h4><strong>Future Opportunities in Chromatography and Mass Spectrometry</strong></h4><p>Looking ahead, Kelly sees significant innovation opportunities in:</p><ul><li>Greater integration of analytical platforms</li><li>Faster chromatographic separations</li><li>Enhanced multiplexing</li><li>Smarter data analytics</li><li>Increased automation</li><li>Real-time process monitoring</li><li>Process analytical technologies (PAT)</li></ul><p>These developments will bring analytical insights closer to manufacturing environments and improve efficiency across the drug development lifecycle.</p><h4><strong>The Next 5–10 Years</strong></h4><p>Over the next decade, Kelly expects analytical workflows to become:</p><ul><li>More predictive</li><li>More automated</li><li>More interconnected</li><li>Increasingly supported by AI-driven interpretation</li></ul><p>However, she emphasized that these advances must remain grounded in high-quality analytical data generated by ultra-high-resolution instrumentation.</p><h4><strong>Final Thoughts</strong></h4><p>Kelly concluded by highlighting the critical role analytical scientists play in enabling patient access to safe and effective medicines. By identifying hidden risks, characterizing complex molecules, and supporting innovation without compromising scientific rigor, analytical science remains a cornerstone of modern drug development and aligns directly with Thermo Fisher Scientific's mission of making the world healthier, cleaner, and safer.</p><blockquote><p><strong>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</strong></p></blockquote><blockquote><h4><strong>Concentrating on Chromatography Podcast</strong></h4><p>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!</p><p>You can find <strong>Concentrating on Chromatography Podcast </strong>in podcast apps:</p><ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL"><strong>Spotify</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185"><strong>Apple podcast</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography"><strong>podscan</strong></a></li></ul><p>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos"><strong>YouTube channel</strong></a></p></blockquote>

How GLP-1 Drugs Are Analyzed: Chromatography & Mass Spectrometry Explained

<p><strong>In the week of June 15, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.</strong></p><blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars"><strong>👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</strong></a></h4><p><strong>👉 Search and filter in the largest global database</strong> with over <strong>5 500 GC, LC, MS and spectroscopy webinars</strong>.</p></blockquote><h5><strong>1. Agilent Technologies: Innovations and Emerging Tools in Peptide Science</strong></h5><ul><li>Tu, 16.6.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6252">Registration</a></li></ul><p>Master peptide characterization and manufacturing. Discover Agilent solutions for GLP-1 API scale-up, xCELLigence cell-based bioassays, non-destructive Raman RMID, and inert LC/MS impurity profiling workflows.</p><h5><strong>2. Waters Corporation: DMPK: From Sample to Result</strong></h5><ul><li>Tu, 16.6.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6227">Registration</a></li></ul><p>Discover practical DMPK bioanalysis workflows in action and learn how modern software and MS systems improve efficiency, consistency, and confidence from sample to result.</p><h5><strong>3. Waters Corporation: Which Detector Do You Need for GLP-1RAs? Choosing Between MALS and Mass Spec</strong></h5><ul><li>Tu, 16.6.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6250">Registration</a></li></ul><p>This webinar explains how multi-angle light scattering (MALS) and mass spectrometry (MS) provide complementary insights into GLP-1RA quality.</p><h5><strong>4. Phenomenex: Enabling Robust HILIC LC–MS Workflows for Highly Polar Compound Analysis</strong></h5><ul><li>We, 17.6.2026 10:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6254">Registration</a></li></ul><p>Enable robust HILIC LC-MS workflows for highly polar compounds. Learn how Kinetex Amide columns provide consistent retention, high selectivity, and excellent reproducibility in complex matrices.</p><h5><strong>5. Waters Corporation: Development and Implementation of an Efficient LC-TOF MS Screening Workflow in Seized Drug Analysis</strong></h5><ul><li>We, 17.6.2026 16:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6272">Registration</a></li></ul><p>The upcoming webinar will address how the Acquity UPLC with the RDa detector has been employed to develop a workflow for screening seized drug cases.</p><h5><strong>6. Waters Corporation: Charge! Next-Generation LNP Assays with Waters Reversed Phase Charge Aerosol Detection</strong></h5><ul><li>We, 17.6.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6258">Registration</a></li></ul><p>Optimize lipid nanoparticle separations. Discover new lipid stationary phases and method development strategies for LNP composition and impurity analysis using UV, ELSD, CAD, and MS detection.</p><h5><strong>7. Waters Corporation: Advancing Size Exclusion Chromatography (SEC) for Characterization of Genetic Therapeutics</strong></h5><ul><li>Th, 18.6.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6259">Registration</a></li></ul><p>Optimize size exclusion chromatography for genetic therapeutics. Learn how wide-pore SEC columns enable high-resolution profiling of mRNA, LNPs, and viral vectors while preventing shear degradation.</p><h5><strong>8. Metrohm: From Challenge to Confidence: PFAS Analysis with Ion Chromatography-Based Techniques</strong></h5><ul><li>Th, 18.6.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6264">Registration</a></li></ul><p>Master comprehensive PFAS water analysis. Learn how Combustion IC (CIC) determines total AOF, and discover how IC-MS/MS quantifies highly hydrophilic ultra-short chain PFAS like trifluoroacetic acid (TFA).</p><h5><strong>9. Evosep Biosystems: Assay Development for translational and research applications</strong></h5><ul><li>Th, 18.6.2026 16:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6265">Registration</a></li></ul><p>Discover how the Evosep Eno system, when combined with the Orbitrap Exploris 480 instrument, enables high-throughput proteomic analysis of plasma for machine learning models.</p><h5><strong>10. Unchained Labs: Know the ins and outs of your lentivirus with Leprechaun</strong></h5><ul><li>Th, 18.6.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6266">Registration</a></li></ul><p>Optimize lentivirus characterization for in vivo CAR-T therapies. Learn how Leprechaun combines interferometry and fluorescence to deliver complete size and structural data on individual viral particles.</p><h5><strong>11. Technology Networks: Selecting Biomarker Methods for Evolving Oncology Research Workflows</strong></h5><ul><li>Th, 18.6.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6260">Registration</a></li></ul><p>Select the right biomarker methods for precision oncology. Balance sensitivity with turnaround time.</p><h5><strong>12. SelectScience: Native fluorescence detection for high-throughput CE-SDS and AAV characterization in drug development</strong></h5><ul><li>Fr, 19.6.2026 17:30 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6268">Registration</a></li></ul><p>Enhance CE-SDS and AAV characterization. Learn how native fluorescence detection (NFD) on the BioPhase 8800 system improves signal-to-noise ratios without protein labeling or workflow complexity.</p>

Webinars LabRulezLCMS Week 25/2026

<p><strong>This study systematically compares four widely used lysosome enrichment strategies, including density gradient separation, magnetic bead isolation, filter-based enrichment, and subcellular fractionation. Using the THP-1 monocytic cell line, the methods were evaluated for lysosome yield, purity, membrane integrity, reproducibility, scalability, and contamination through complementary analytical techniques and proteomics.</strong></p><p>The results showed that gradient- and bead-based methods achieved the highest lysosomal purity, while subcellular fractionation yielded larger numbers of lysosomes but with greater contamination and variability. Filter-based enrichment enabled rapid processing but recovered mainly nonintact lysosomes. The findings provide practical guidance for selecting lysosome isolation methods in both research and clinical applications.</p><blockquote><h4><strong>The original article</strong></h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05792"><strong>Benchmarking Lysosome Enrichment Methods: A Guide for Research and Clinical Translation</strong></a></h4><p>Anniek L. de Jager, Sara Kassem, Louis Alesha, Brigitta A.E. Naber, Inge F. de Laat, Bas de Mooij, Kyra van der Pan, Erik Bos, Roman I. Koning, Jacques J.M. van Dongen*, Cristina Teodosio*, and Paula Díez*</p><p>Anal. Chem. 2026, 98, 6, 4585–4600</p><p><a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1021/acs.analchem.5c05792">https://doi.org/10.1021/acs.analchem.5c05792</a></p><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/"><strong>CC-BY 4.0</strong></a></h6></blockquote><p><strong>Selected sections from the article follow. Formats and hyperlinks were adapted from the original.</strong></p><div><p>Since their discovery by De Duve et al. <a href="javascript:void(0);">(1)</a> in 1955, lysosomes have emerged as dynamic organelles critical to cellular homeostasis, regulating processes from nutrient sensing to plasma membrane repair. <a href="javascript:void(0);">(2−5)</a> These acidic, enzyme-packed vesicles <a href="javascript:void(0);">(6,7)</a> are now acknowledged as central players in pathologies far beyond their classical association with lysosomal storage disorders (LSDs). Dysfunctional lysosomes are involved in neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s), <a href="javascript:void(0);">(8−10)</a> cancer metastasis, <a href="javascript:void(0);">(11−13)</a> and cardiovascular disorders. <a href="javascript:void(0);">(14,15)</a> At the same time, lysosomal proteins like GBA1 and LAMP2 serve as biomarkers and therapeutic targets. <a href="javascript:void(0);">(16−19)</a> Despite their clinical significance, a major challenge in lysosomal research persists since lysosomes constitute less than 5% of cellular volume, <a href="javascript:void(0);">(20,21)</a> requiring precise enrichment for accurate analysis in diagnostic and therapeutic development. <a href="javascript:void(0);">(22,23)</a></p><p>Current lysosome isolation methods, including density gradient-based separation, <a href="javascript:void(0);">(24−28)</a> filter-based size exclusion approaches, <a href="javascript:void(0);">(29)</a> magnetic particle phagocytosis, <a href="javascript:void(0);">(30−33)</a> subcellular fractionation (SCF), <a href="javascript:void(0);">(34)</a> and immunoprecipitation strategies, <a href="javascript:void(0);">(35,36)</a> vary widely in yield, purity, structural integrity, and practicality. For instance, density gradient-based methods, which often use Percoll <a href="javascript:void(0);">(37)</a> or sucrose, <a href="javascript:void(0);">(38)</a> while well-established, user-friendly, and cost-effective, coisolate organelles with similar densities, such as endosomes, peroxisomes, and mitochondria, <a href="javascript:void(0);">(39,40)</a> and can be time-consuming, potentially affecting lysosomal protein integrity. Conversely, filter-based size exclusion methods isolate lysosomes based on their size, <a href="javascript:void(0);">(29)</a> offering shorter processing times and straightforward protocols. Nevertheless, these approaches may result in cross-contamination, as various cellular vesicles share similar sizes. <a href="javascript:void(0);">(20,21)</a> Magnetic bead-based methods (e.g., superparamagnetic iron oxide nanoparticles, SPION) involve the endocytic uptake of magnetic beads, <a href="javascript:void(0);">(35,41)</a> offering specificity but altering lysosomal physiology through forced phagocytosis, which hampers functional assays, such as in cancer drug screening. <a href="javascript:void(0);">(42,43)</a> Finally, SCF, which employs sequential lysis steps to enrich specific organelles, including lysosomes, <a href="javascript:void(0);">(34,44)</a> is a rapid, easy-to-use, and cost-effective method; however, significant cross-contamination is linked to this method. <a href="javascript:void(0);">(34,44)</a> Such trade-offs are rarely addressed in single-modality studies, leaving clinicians and researchers without clear guidance for protocol selection. This gap is particularly critical in translational contexts, where diagnostic laboratories that prioritize high-purity lysosomes for biomarker discovery require protocols different from those of therapeutic teams that need lysosomes for drug efficacy testing.</p><p>Previous comparative studies, such as the proteomic analysis by Singh et al., <a href="javascript:void(0);">(35)</a> have provided valuable insights but primarily focused on yield and purity assessments via proteomic markers, overlooking several key parameters with potentially relevant impacts in translational and clinical applications. Critically, these studies often omit functional and practical metrics: for instance, they typically do not evaluate lysosomal membrane integrity, which is vital for enzyme activity and therapeutic testing, nor do they consider the scalability and feasibility of protocols for contexts where only limited patient samples are available or the potential presence of isolation artifacts. This omission of practical, multimodal assessment represents a critical gap that prevents researchers from selecting a protocol optimized for specific clinical goals.</p><p>Our study seeks to address these limitations by employing a multimodal framework that evaluates four widely used lysosome isolation methods across several metrics that are critical for clinical applications. We systematically assessed the yield and reproducibility of each method, factors that are essential for biobanking and high-throughput diagnostic workflows. We also examined organelle purity, crucial for avoiding false positives in proteomic biomarker screenings, together with lysosomal membrane integrity, an important consideration for functional studies and drug testing. Finally, we considered the scalability of each method, ensuring that our findings are relevant for studies involving rare or precious patient-derived cells together with the cost and processing time of each technique. Thus, by integrating nanoparticle tracking analysis (NTA), spectral flow cytometry, transmission electron microscopy (TEM), and mass spectrometry (MS)-based proteomics, our study revealed distinct advantages for each method depending on the intended application. With this comprehensive benchmark, we bridged a critical gap between fundamental lysosome biology and clinical implementation, guiding researchers and clinicians in the selection of the most appropriate isolation strategies tailored to their diagnostic or therapeutic goals.</p><h3><strong>Experimental Section</strong></h3><h4><strong>Liquid Chromatography–Tandem Mass Spectrometry Analysis (LC–MS/MS)</strong></h4><p>For liquid chromatography–tandem mass spectrometry (LC–MS/MS) studies, a total of 15 μg of proteins were reduced with 10 m<span>M</span> DTT at 45 °C for 30 min, followed by alkylation with 40 m<span>M</span> 2-iodoacetamide (IAA, Sigma-Aldrich) at RT for 30 min. This last reaction was quenched with 20 m<span>M</span> DTT, and protein digestion and peptide recovery were performed using hydrophilic and hydrophobic beads (Sera-Mag Carboxylate-Modified Magnetic Particles, Cytiva, Marlborough, MA/USA) according to the Single-Pot Solid-Phase-enhanced Sample Preparation (SP3) method. <a href="javascript:void(0);">(46,47)</a> In short, samples were incubated twice with beads (1:10 (w/w) protein:bead ratio) in 70% acetonitrile (ACN) for 18 min at RT. After incubation, bead-bound proteins were retained by using a DynaMag-PCR Magnet (Thermo Fisher), and contaminants were washed away three times with 80% ethanol (Sigma-Aldrich). Proteins were digested using a Trypsin/LysC mix (1:25 (w/w) enzyme:protein ratio, Promega, Madison, WI/USA) in 50 m<span>M</span> ammonium bicarbonate at RT overnight. Beads were then washed twice with ACN, after which peptides were eluted in 2% (v/v) dimethyl sulfoxide (DMSO, Thermo Fisher), lyophilized in a freeze-dryer, and stored at −20 °C. Samples were then tagged using the tandem mass tag (TMT) labeling kit (TMTpro 16plex tags, Thermo Fisher) by resuspending the lyophilized peptides in 40 m<span>M</span> HEPES pH 8.4 and labeling with the TMT tags at a 1:5 (w/w) sample:tag ratio for 1 h at RT. The labeling reaction was quenched with 5% hydroxylamine. TMT-labeled lysosome samples were pooled, lyophilized in a freeze-dryer, and stored at −20 °C until LC–MS/MS analysis.</p><h4><strong>Mass Spectrometry Data Acquisition and Analysis</strong></h4><p>MT-labeled peptides were dissolved in solvent A (water/formic acid (FA), 100/0.1 (v/v)) and analyzed by online C18 nano-HPLC MS/MS, coupling an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=3&amp;search=UltiMate+3000"><strong>UltiMate 3000 gradient HPLC system</strong></a> (Thermo Fisher) and an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/401"><strong>Orbitrap Exploris 480 mass spectrometer</strong></a> (Thermo Fisher). A total of 12 fractions were injected onto a precolumn (300 μm × 5 mm; PepMap100 C18 5 μm, Thermo Fisher) equilibrated with solvent A and eluted via a homemade analytical nano-HPLC column (50 cm × 75 μm; ReproSil-Pur C18-AQ 1.9 μm) using solvent B (80/20/0.1 (v/v/v) ACN/water/FA) in a gradient from 5 to 30% in 160 min. The nano-HPLC column was drawn to a tip of ∼5 μm and functioned as an electrospray needle. A Sonation PRSO-V2 column oven was used to maintain the analytical column temperature at 50 °C. The MS1 spectra were recorded in the Orbitrap at a mass-to-charge ratio (<i>m</i>/<i>z</i>) range of 350–1,600, a resolution of 120,000, a maximum injection time of 50 ms, and automatic gain control (AGC) at standard. Dynamic exclusion was applied after <i>n</i> = 1 with an exclusion duration of 45 s and a mass tolerance of 10 ppm. Charge states 2–5 were included. Precursors for MS2 were selected using a TopSpeed method of 3 s at a resolution of 45,000 and fragmented by high-energy collision-induced dissociation (HCD) at a normalized collision energy (NCE) of 36%, with an AGC at 200 and the maximum injection time set to auto. The isolation window for MS/MS was 1.2 Da.</p><p>Raw data files were converted to the peak list by using <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1782"><strong>Proteome Discoverer v2.4</strong></a> (Thermo Fisher), followed by protein identification employing the UniProtKB database (<i>Homo sapiens</i>, 20,596 entries) using Mascot v2.2.07 (Matrix Science Inc., Boston, MA/USA) with the following parameters: precursor and fragment mass tolerances of 10 ppm and 0.02 Da, respectively; TMT16plex on N-term and Lys as fixed modifications; oxidation on Met and acetylation of N-term as variable modifications; and full tryptic digestion (no P rule) with up to 2 missed cleavages. A false discovery rate (FDR) of 1% was set for peptide spectrum matches (PSMs), peptides, and proteins.</p><p>The MS data have been deposited via the PRIDE partner repository to the ProteomeXchange Consortium with the identifier PXD040003.</p><h3><strong>Results</strong></h3><h4><strong>Quantification and Size Distribution of Isolated Vesicle Fractions</strong></h4><p>To assess the yield and size distribution of vesicles isolated by different methods, nanoparticle tracking analysis (NTA) was employed. The SCF procedure yielded the highest median number of vesicles per cell (2,356.3 ± 7,461.7; median ± range), followed by gradient-based (1,630.2 ± 1632.3), filter-based (228.2 ± 265.6), and bead-based isolation (27.8 ± 35.2). Both filter- and bead-based approaches resulted in significantly lower yields compared to SCF (<i>p</i>-value = 0.002 and <i>p</i>-value &lt;0.0001, respectively), and the gradient-based method yielded significantly more vesicles than the bead-based approach (<i>p</i>-value = 0.002; <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05792#fig1">Figure 1</a>A).</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2026_98_6_4585_4600_Figure_1_Quantification_and_size_analyses_of_isolated_vesicles_2d5c120f05.jpeg" alt="Anal. Chem. 2026, 98, 6, 4585–4600: Figure 1. Quantification and size analyses of isolated vesicles. A) Quantification of isolated vesicles per cell, shown as median with range. Circles represent technical replicates. B) Size distribution of isolated vesicles (in nm), displaying average D10 (red), D50 (blue), and D90 (gray), depicted as median with range. Circles represent technical replicates. C–F) Particle distribution plots showing mean concentration at specific sizes; each line represents a technical replicate. For each method, six technical replicates are shown, except for SCF, which includes 12 replicates. SCF, subcellular fractionation. Statistical significance: p &lt; 0.05 and FDR 5%. For statistical analysis, the nonparametric Kruskal–Wallis test was used and corrected for multiple comparisons using the method of Benjamini and Hochberg." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2026_98_6_4585_4600_Figure_1_Quantification_and_size_analyses_of_isolated_vesicles_2d5c120f05.jpeg 126w," sizes="100vw" width="1383" height="1708"></p><p>Median vesicle size (D50) was comparable across all methods: 159.5 ± 17.2 nm (gradient-based), 169.9 ± 82.7 nm (filter-based), 168.9 ± 42.4 nm (bead-based), and 150.0 ± 55.6 nm (SCF). Similarly, decile 10 (D10) values were consistent, ranging from 87.1 ± 87.3 nm (SCF) to 108.2 ± 3.1 nm (gradient-based). However, filter-based isolation led to higher size heterogeneity of the isolated particles, capturing significantly larger vesicles at the upper end (D90:308.5 ± 110.7 nm) compared to SCF (244.9 ± 112.6 nm, <i>p</i>-value = 0.005), while gradient- and bead-based methods showed intermediate D90 values (250.8 ± 31.7 nm and 273.0 ± 45.9 nm, respectively; <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05792#fig1">Figure 1</a>B). Notably, greater intra-assay variation in concentration and size distribution was observed with filter-based and SCF methods compared to the other approaches (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05792#fig1">Figure 1</a>C–F).</p><h4><strong>Morphology of the Isolated Fractions</strong></h4><p>Transmission electron microscopy (TEM) of the isolated fractions confirmed the presence of heterogeneously sized vesicles, in line with the size distributions obtained by NTA. Notably, only the gradient-based method yielded relatively pure vesicle preparations. In contrast, filter-based and SCF methods displayed contamination with cellular debris or protein aggregates, while the bead-based approach was associated with the presence of lipid structures (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05792#fig2">Figure 2</a>).</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2026_98_6_4585_4600_Figure_2_Transmission_electron_microscopy_TEM_of_isolated_fractions_f14ddbe180.jpeg" alt="Anal. Chem. 2026, 98, 6, 4585–4600: Figure 2. Transmission electron microscopy (TEM) of isolated fractions. Panels A–D show TEM images of the four isolated fractions. Insets display magnified views of the regions outlined in black squares. Black arrows indicate identified representative isolated vesicles, and white arrows denote areas of contamination." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2026_98_6_4585_4600_Figure_2_Transmission_electron_microscopy_TEM_of_isolated_fractions_f14ddbe180.jpeg 145w," sizes="100vw" width="1263" height="1361"></p><h3><strong>Conclusion</strong></h3><p>This study provides a systematic benchmarking of four lysosome isolation strategies, revealing inherent trade-offs among yield, integrity, purity, and reproducibility driven by their underlying separation principles. No single method is universally optimal; instead, the method selection must be guided by the intended downstream application. By integrating complementary analytical approaches in a clinically relevant and challenging monocytic model, our work offers a practical framework to support the informed selection of lysosome enrichment strategies, facilitating reliable lysosomal analyses in both research and translational settings.</p></div>

Benchmarking Lysosome Enrichment Methods: A Guide for Research and Clinical Translation

Article

Webinars

Video

Scientists

Scientific article

Interview

Science and research

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Metrohm

Agilent Technologies

Unchained Labs

Phenomenex

Evosep Biosystems

Waters Corporation

<h4><strong>Tackle Real Workflows for Complex Bioanalysis Challenges</strong></h4><ul><li>Working in DMPK?</li><li>Curious how modern software is making workflows for new modalities easier?</li></ul><p>We’re excited to invite you to DMPK in Action, a new 3-part webinar series designed for &nbsp;bioanalysis scientists that brings real workflows to your screen through practical demonstrations of our system and software.</p><h5><strong>See real DMPK workflows in action - designed for the challenges of modern, complex therapeutics.</strong></h5><p>In short 30 min sessions, we’ll show real workflows, with a focus on practical applications, efficiency, and how DMPK scientists can move from sample to result with greater confidence.</p><h5><strong>Episodes</strong></h5><ul><li>Explore the DMPK workflow in action</li><li>From Sample to Result</li><li>Data handling and analysis with confidence</li></ul><h5><strong>Why you should attend</strong></h5><p>Each session shows how our system and software support practical DMPK tasks, improve visibility, and help teams work more efficiently.</p><h5><strong>You'll see:</strong></h5><ul><li>Real DMPK workflow demonstrations.</li><li>Practical use cases for bioanalysis scientists.</li><li>How our system and software support consistency, reliability, and efficiency.</li></ul><h5><strong>Who should attend</strong></h5><p>If you’re involved in DMPK, bioanalysis, or ADME workflows, this series is designed to give you a clear look at how the process works in practice, delivered straight to your office</p><p><i>Can't attend the webinars live? Register today and watch the episodes on-demand at your convenience.</i></p><blockquote><p><strong>Speaker:</strong> Antonia Wierzbicki (Principal MS Market Dev Manager, EMEA, Waters Corporation)</p><p>Antonia Wierzbicki is a MS market development manager at Waters working in EMEA. Antonia has BSc in Pharmaceutical Science and a MSc in Cancer Pharmacology.</p><p>Following several years working as an analytical chemist in drug development roles within both academic labs and contract research organizations, Antonia has more recently spent time working with analytical chemists to provide solutions using cutting edge technologies to meet their needs and requirements, with a specific interest in ultra-sensitive quantitation of small molecules.</p><p>Antonia is based in Cambridge UK and keen to connectwith like-minded scientists in the field.</p><p><strong>Speaker:</strong> Henry Foddy (Associate Scientist, Waters Corporation)</p><p>Henry is a Scientist in the Routine Mass Detection Team at Waters, working on applications to support Waters’ single quadrupole portfolio that span a variety of market segments. He has almost 3 years of experience with Waters, working previously in a food and environmental role support regulatory testing of Pesticides, PFAS, and Pyrrolizidine Alkaloids. Prior to joining Waters, Henry obtained an MSc in Neuroscience from King’s College London.</p></blockquote>

DMPK: From Sample to Result

Join Waters webinars on DMPK bioanalysis workflows, data handling, and modern software tools supporting efficient ADME and bioanalysis applications.

<div><p><strong>Two Powerful Detectors, One Complete Picture:</strong></p><p><strong>MALS and MS for GLP-1RA Characterization</strong></p><p>Which advanced detector should you use for GLP-1 receptor agonists - and when?</p><p>This webinar explains how multi-angle light scattering (MALS) and mass spectrometry (MS) provide complementary insights into GLP-1RA quality.</p><h5><strong>What You'll Learn:</strong></h5><p>Learn when to use SEC-MALS for direct molar mass and oligomer quantitation in solution, and when RPLC-MS is essential to confirm molecular identity and detect chemical variants.</p><p>Through practical examples, discover how these orthogonal techniques strengthen CQA assessment, improve analytical confidence, and guide effective column selection for separation.</p><p>The session also highlights compliant, integrated workflows using Empower Chromatography Data System.</p><ul><li>Choose the right detector with confidence: Understand when to use MALS for oligomer and aggregation analysis and when MS is essential for confirming molecular identity and chemical variants.</li><li>Accelerate method development with the right column: Learn practical SEC and RPLC column selection strategies, plus resources to help you get started quickly.</li><li>Discover the latest capabilities in Empower Software: Simplify SEC-MALS and MS workflows, improve efficiency, and support compliant data analysis.</li></ul><p><strong>Reserve Your Spot Today!</strong></p><p>This webinar is designed for Scientists, Analysts, and Lab Managers in Discovery, Development, Quality Control, or Analytical Services who characterize synthetic peptides, CDMOs, CROs and other testing organization who are interested in expanding their capabilities<br>&nbsp;</p><blockquote><p><strong>Speaker:</strong> Udayabagya (Bud) Halim (Sr. Product Marketing Analyst, Waters Corporation)</p><p>Bud Halimis a senior marketing analyst at Waters | Wyatt Technology with a PhD in physical chemistry from UCLA.</p><p>He began his career teaching biochemistry and chemistry and contributing to laboratory manuals before transitioning into the scientific instrumentation industry as an applications scientist.</p><p>At Waters, he supports researchers in the characterization of peptides, biologics, lipid nanoparticles (LNPs), and viral vectors.</p></blockquote></div>

Waters Corporation: Which Detector Do You Need for GLP-1RAs? Choosing Between MALS and Mass Spec

Which Detector Do You Need for GLP-1RAs? Choosing Between MALS and Mass Spec

Master GLP-1RA characterization. Discover when to use SEC-MALS for aggregation analysis and when RPLC-MS is essential to confirm molecular identity

MALS and MS for Advanced GLP-1RA Characterization

<p><strong>Discover how today’s advanced peptide technologies are shaping tomorrow’s research, development, and manufacturing success.</strong></p><h5><strong>In this symposium, you'll learn about:</strong></h5><ul><li>Scalable peptide API manufacturing and purification expertise for GLP‑1 class molecules</li><li>Label‑free, real‑time cell‑based bioassays for peptide activity, optimization, and safety testing</li><li>Non‑destructive Raman raw material identification through opaque containers to streamline GMP workflows</li><li>Inert LC/MS strategies for enhanced peptide separation, impurity profiling, and molecular weight confirmation</li></ul><p>This digital symposium explores the innovations shaping the future of peptide‑driven science, featuring modern analytical tools across cell analysis, chemistries, spectroscopy, and mass spectrometry. Experts will reveal practical approaches for integrating these technologies to strengthen and streamline peptide analysis.</p><p>Attendees will gain a clear view of emerging technologies and practical strategies across modern research and applied science. Join the symposium to discover how to connect these advances directly to your own work.</p><p><strong>10:00 - 10:05 - Intro</strong></p><p>Vitan Blagotinsek, Agilent Technologies</p><p><strong>10:05 - 10:20 - Highlight Talk - Scaling the GLP-1 Surge: Peptide API Development, Purification and Manufacturing at AAT</strong></p><p>Wolfgang Schiek, BioVectra</p><p>As the paradigm shift in diabetes management and the surge in anti-obesity drug sales and development are propelling unprecedented demand for complex peptide APIs therapies, reliable high quality peptide API manufacturing and purification are critical. Agilent Advanced Therapeutics provides specialized expertise and scaling capacity for these GLP-1 Agonists. We support our customers from preclinical to commercial through swift, customer-focused implementation in state-of-the-art facilities and are continuously expanding capabilities, true to our commitment: Invested in Science, Invested in You!</p><p><strong>10:20 - 11:05 - Talk 1: Accelerating Synthetic Peptide Discovery, Quality Control, and Safety Testing with xCELLigence Bioassay</strong></p><p>Leyna Zhao, Agilent Technologies</p><p>Synthetic peptides and proteins are rapidly emerging as important therapeutic modalities, driving the need for robust approaches to evaluate biological activity, product quality, and safety throughout development. In this webinar, we will explore how Agilent’s label free xCELLigence Real Time Cell Analysis (RTCA) platforms can support synthetic peptide discovery, quality evaluation, and safety testing through functional, cell based bioassays. Selected case studies will highlight the use of real time, kinetic cellular readouts in peptide discovery and optimization workflows. Evaluation criteria for biological products will be reviewed in the context of ICH Q6B specifications, with emphasis on the role of bioassays in assessing biological activity. In addition, examples of toxicity testing using xCELLigence RTCA—including published vaccine related applications—will demonstrate how real time cell based assays can provide sensitive and reproducible QC results.</p><p><strong>11:10 - 11:50 - Talk 2: Unlocking Deeper Insights into Peptide Purity and Impurity Profiling with LC/MS for GLP-1 RA Characterization</strong></p><p>Holger Stalz, Agilent Technologies</p><p>Synthetic Peptide therapeutics are reshaping the biopharma landscape, and GLP-1 receptor agonists are at the center of that momentum—raising the stakes for purity assessment and impurity profiling. Join this webinar to see how Agilent’s advanced LC/MS workflows help scientists tackle these challenges with greater confidence and efficiency. You’ll learn how the InfinityLab Pro iQ Plus LC/MSD enables reliable peptide purity confirmation, while the Agilent BioQTOF high-resolution LC/MS/MS system supports detailed sequence confirmation and impurity identification. We’ll also show how OpenLab CDS and MassHunter BioConfirm software simplify complex data interpretation, helping QC and R&amp;D teams move faster and make more confident decisions in peptide characterization.</p><p><strong>11:55 - 12:35 - Talk 3: Raman Spectroscopy in Peptide Pharmaceuticals</strong></p><p>Jan Wuelken, Agilent Technologies</p><p>Rapid, non destructive raw material identification (RMID) through all types of packaging. Reliable identity verification of peptides, amino acids, protected building blocks, and excipients is a critical step in peptide manufacturing. The Agilent Vaya Raman Raw Material Identity Verification System is specifically designed to identify raw materials directly through non transparent and opaque containers, without opening the package. By leveraging Spatially Offset Raman Spectroscopy (SORS), Vaya minimizes interference from container walls, liners, and fluorescence. This enables fast and reliable identification through typical peptide pharma packaging, including plastic drums, paper and multi layer bags, FIBCs, and amber glass containers. The through container measurement capability eliminates the need for sampling, significantly reducing the risk of cross contamination and protecting operators from hazardous, highly potent, or sterile materials. At the same time, it streamlines workflows by reducing handling steps and operator exposure. Agilent Vaya supports high throughput, GMP compliant raw material testing, accelerates release to manufacturing, and helps ensure a secure, efficient supply of materials for peptide synthesis and downstream processing—from early development to commercial production.</p><p><strong>12:40 - 13:15 - Talk 4: Advanced Column Solutions to enhance your Peptide Analysis and Purification Workflows</strong></p><p>Katrien Sabbe, Agilent Technologies</p><p>Whether you're optimizing existing methods or developing new ones, this session will equip you with the tools to streamline your peptide characterization and purification. LC analysis of peptides can be challenging due to their sensitivity to metal interactions within chromatographic systems, often leading to poor peak shape and reduced sensitivity. Agilent Altura HPLC columns with Ultra Inert technology overcome these challenges by minimizing metal-analyte interactions. We will illustrate how this innovation enhances resolution, reproducibility, and quantification in reversed phase and HILIC separations of therapeutic peptides such as GLP-1 receptor agonists. Furthermore we will explore preparative techniques and purification workflows, offering tips for achieving high purity and recovery in synthetic peptide purification.</p><blockquote><p><strong>Presenter: </strong>Vitan Blagotinsek (EMEA Marketing Program Manager Bio/Pharma, Agilent Technologies)</p><p>Vitan is the Agilent Marketing Manager for the Pharma and Biopharma markets across the EMEA region, covering a broad portfolio of all Agilent products with relevance to these markets. Prior to this role, he had started at Agilent as a Chromatography and Sample prep-focused Product Specialist targeting the Biopharma market in the DACH region. His scientific background is in Protein Biochemistry/Structural Biology. He graduated in Biochemistry from the University of Oxford in the UK and has a PhD from Marburg University in Germany (Department of Chemistry).</p></blockquote><blockquote><p><strong>Presenter:&nbsp;</strong>Wolfgang Schiek (Director Business Development, BIOVECTRA, Agilent Technologies)</p><p>Wolfgang is the BD Director Europe for Agilent Advanced Therapeutics, where he specializes in bespoke CDMO solutions and a chemist by profession. With a 25-year track record at industry leaders like Evonik, Cambrex, and Novasep in a variety of technical, commercial and strategic roles, he has helped numerous clients bridge the gap from drug development to successful market launch. For the past four years at AAT, he has focused on the cutting edge of biologics and peptides, serving as one of the primary forces behind the company’s GLP-1 programs.</p></blockquote><blockquote><p><strong>Presenter: </strong>Leyna Zhao (Product Marketing Director, Agilent Technologies)</p><p>Leyna is Product Marketing Director at Agilent Technologies, where she leads global strategy for cell analysis platforms, including xCELLigence Real-Time Cell Analysis (RTCA). With over 20 years of experience in molecular biology, immunology, and drug discovery, she bridges scientific innovation with market adoption. Her work focuses on advancing label-free, real-time technologies that support small molecule screening, immune cell function analysis, and predictive toxicology. She holds a PhD in Biochemistry and has been instrumental in aligning Agilent’s cell analysis solutions with emerging regulatory trends, such as non-animal testing methodologies.</p></blockquote><blockquote><p><strong>Presenter: </strong>Jan Wuelfken (Product Specialist, Molecular Spectroscopy EMEA IDO, Agilent Technologies)</p><p>Jan graduated from the University of Hamburg in 1997 with a thesis about NMR-based conformation analysis of an antimicrobial peptide and in 2001 with his PhD thesis about CD4-binding peptides as inhibitors for HIV infection. He joined Varian Inc. in 2001 as a sale representative for molecular spectroscopy and with the takeover of Varian by Agilent 2010 he became a product specialist for molecular spectroscopy in the Agilent International Distributor Organization (IDO). Today his responsibility is the full Agilent Molecular Spectroscopy Portfolio which is UV-Vis, UV-Vis/NIR, Fluorescence, FT-IR and Raman Spectroscopy.</p></blockquote><blockquote><p><strong>Presenter:&nbsp;</strong>Holger Stalz (LCMS Product Specialist, Agilent Technologies )</p><p>Holger has worked as a product specialist for LC/MS for Agilent in Austria and Switzerland since 2011. He leads a team of European BioPharma Specialists focusing on biopharmaceutical applications and has been coordinating the development of new analytical solutions and methods for protein therapeutics and oligonucleotide-based products.</p></blockquote><blockquote><p><strong>Presenter:&nbsp;</strong>Katrien Sabbe (Biopharma Business Development Manager, Agilent Technologies)</p><p>For more then 25 years Katrien has been working in the field of Chromatography Columns and Supplies, first at VWR International and later at Varian Analytical Instruments, which was acquired in 2011 by Agilent Technologies. Currently, she is the EMEA Biopharma Business Development Manager at Agilent Technologies Chemistries and Supplies Division.</p></blockquote>

BiteSizeBio: Innovations and Emerging Tools in Peptide Science

Innovations and Emerging Tools in Peptide Science

Explore advanced peptide technologies. Learn about GLP-1 API manufacturing, xCELLigence bioassays, through-container Raman RMID, and inert LC/MS workflows

Advanced Peptide Technologies and GLP-1 Analysis

<p><strong>This webinar will highlight the role of Kinetex® Amide in enabling robust and reliable HILIC LC–MS workflows for the analysis of highly polar compounds in complex matrices.</strong><br>Practical application examples will include the determination of residual lactose in dietary supplements to support lactose-free claims, along with method optimization under TFA and DFA mobile phase conditions.<br>Attendees will gain hands-on insights into how Kinetex Amide delivers consistent retention, high selectivity, and excellent reproducibility, while preserving full LC–MS compatibility and supporting high laboratory productivity.</p><h5><strong>Key Learning Points</strong></h5><ul><li>Understand key considerations for HILIC LC–MS analysis of highly polar compounds.</li><li>Learn how to improve HILIC method robustness, reproducibility, and throughput in routine analysis.</li><li>Listen to a real case study of very polar compounds (amino acids, lactose, and organic acids).</li><li>Find how to apply robust workflows for lactose determination in lactose‑free products.</li><li>Review TFA and DFA determination in water.</li></ul><h5><strong>Who Should Attend</strong></h5><ul><li>Any LC and LC–MS users working in food, environmental and pharmaceutical laboratories who are involved in:</li><li>Analysis of highly polar compounds</li><li>Verification of lactose‑free products and simple sugar</li><li>Amino acid analysis</li><li>TFA and DFA Analysis</li><li>Routine QC and regulatory testing</li></ul><blockquote><p><strong>Presenter: </strong>Luigi Margarucci (EMEA Seminar &amp; Application Lead, Phenomenex)</p><p>&nbsp;Luigi, who holds a Ph.D. in Pharmaceutical Sciences, has over a decade of experience at Phenomenex. Since 2021, he has served as Technical Manager for Italy and EMEA Seminar &amp; Application Lead. Luigi gained extensive expertise in chromatography coupled with mass spectrometry while working as a researcher at the University of Salerno and collaborating with leading centers in Italy and Europe (including Utrecht University, NL). He is the author of 27 scientific publications and has delivered hundreds of seminars on analytical techniques such as HPLC, GC, and SPE.&nbsp;</p></blockquote>

Phenomenex: Enabling Robust HILIC LC–MS Workflows for Highly Polar Compound Analysis

Enabling Robust HILIC LC–MS Workflows for Highly Polar Compound Analysis

Optimize HILIC LC-MS workflows for highly polar compounds using Kinetex Amide. Improve method robustness for lactose, amino acids, and TFA/DFA analysis.

Robust HILIC LC-MS Workflows with Kinetex Amide

<p><strong>Lipid nanoparticle formulators often struggle to reproducibly separate components and resolve structurally similar analogues that can impact product safety and efficacy.</strong></p><p><strong>Currently, no single reversed-phase column or standardized separation method has been established, resulting in significant time and financial investment in method development.</strong></p><p>In this webinar, we explore the properties and unique selectivity of our new lipid stationary phases, along with best practices and optimization strategies for LNP composition and critical impurity analysis critical for vaccines and emerging in vivo CAR-T. Learn how different detectors can enhance insight, how mobile phase additives can be used to tune selectivity, and how unique stationary phase properties enable robust, efficient method development from discovery through quality testing.</p><h5><strong>Why you should attend</strong></h5><ul><li><strong>Understand how stationary phase properties affect LNP component separation.</strong></li><li><strong>Learn how to tune selectivity by adjusting mobile phases for improved impurities quantitation.</strong></li><li><strong>Identify optimal detection sources with UV, ELSD, CAD, and MS detection.</strong></li></ul><h5><strong>Who should attend</strong></h5><ul><li>Biopharma analytical development scientists</li><li>Process development engineers</li><li>QC and CMC scientists</li><li>Lipid Synthesis chemists</li><li>Lab managers and directors in biologics and advanced therapies</li><li>Academic lab scientists including lipidomics</li></ul><blockquote><p><strong>Speaker: </strong>Mateusz Imiolek, PhD (Principal Scientist, Waters Corporation)</p><p>Mateusz joined Waters in 2022 where he has been studying challenges associated with characterizing gene therapeutics and ensuring that new Waters products are fit for this purpose.</p><p>Before that, he completed his academic training in bioorganic chemistry, which allows him to apply detailed molecular insights to ensure the newly developed columns and assays are carefully designed for such analytes.</p></blockquote><blockquote><p><strong>Speaker: </strong>Adam Kowalczyk (Research Scientist II – Analytical, Acuitas Therapeutics)</p><p>Adam is a Research Scientist II at Acuitas Therapeutics, where he specializes in analytical method development for lipid nanoparticle (LNP)‑based therapeutics. His work focuses on characterizing complex lipid systems, optimizing impurity profiling strategies, and supporting process development through robust analytical data.</p><p>With a strong background in chemistry and hands‑on experience in advanced LC and detection technologies, Adam brings deep technical insight into the challenges and requirements of modern LNP analysis.</p></blockquote>

Charge! Next-Generation LNP Assays with Waters Reversed Phase Charge Aerosol Detection

Improve LNP component separation and impurity analysis. Learn method development strategies using new lipid stationary phases and UV/ELSD/CAD/MS detection

Separation Strategies for Lipid Nanoparticles (LNP)

<p><strong>The rapid growth of genetic medicines - including oligonucleotides, plasmid DNA, mRNA, lipid nanoparticles (LNPs), and viral vectors - has introduced unprecedented analytical challenges. From shear‑induced degradation to poor resolution and reproducibility, traditional SEC approaches often struggle to deliver actionable insights for development, scale‑up, and QC.</strong></p><p>In this webinar, we explore next‑generation SEC columns designed specifically for mega molecules. Discover how wide‑pore SEC technology enables robust, high‑resolution size‑based characterization while preserving sample integrity. Through real‑world examples and best practices, our speaker will demonstrate how modern SEC workflows support faster decision‑making, improved inter‑lab reproducibility, and smoother regulatory pathways for advanced genetic medicine products.</p><h4><strong>What You’ll Learn</strong></h4><h5><strong>Attendees will gain practical insights into:</strong></h5><ul><li>Common SEC challenges in analyzing plasmids, mRNA, LNPs, and viral vectors</li><li>Strategies to minimize shear degradation and maintain biomolecule integrity during separation</li><li>Optimizing SEC methods for mega molecules using wide‑pore column technology</li><li>How to achieve reproducible, high‑resolution separations across labs and sites</li><li>Best practices for method development and extending SEC column lifetime</li><li>How faster SEC workflows can reduce development timelines and support regulatory submissions</li></ul><h4><strong>Why attend?</strong></h4><p>Traditional sizing techniques often fall short when applied to today’s complex, high‑molecular‑weight genetic medicines, leading to low resolution, high variability, and long run times.</p><h5><strong>In this session, you’ll learn how modern wide‑pore SEC solutions:</strong></h5><ul><li>Deliver robust, high‑throughput profiling for early discovery through late‑stage development</li><li>Support multi‑attribute characterization, including size distribution, aggregates, and integrity</li><li>Enable seamless integration with MALS detection for enhanced molecular weight and structural insight</li></ul><h4><strong>Who should attend?</strong></h4><p>This webinar is ideal for analytical scientists, process development teams, QC laboratories, and CROs working in cell and gene therapy, vaccines, and RNA‑based therapeutics.</p><blockquote><p><strong>Presenter: </strong>Ali Tiss, Ph.D., MSc., Eng. (Chemistry Market Development Manager, Biopharma &amp; Cell and Gene Therapies, Waters Corporation)</p><p>Ali joined Waters in 2021 and has since supported colleagues and users in the biomolecule separation field (proteins, peptides, Abs, conjugates, Cell &amp; Gene Therapy products). Ali completed his Ph.D. in biochemistry and structural biology at the Mediterranean University (CNRS, Marseille, France), where he contributed to the R&amp;D of the anti-obesity drug, Xenical®, developed by Roche Ltd. Then, he earned over two decades of research experience in biochemistry, liquid chromatography, mass spectrometry, and proteomics, focusing on detecting and characterizing biomarkers related to human diseases such as cancer, diabetes, and obesity. Ali is passionate about supporting customer business and innovative applications.</p></blockquote>

Advancing Size Exclusion Chromatography (SEC) for Characterization of Genetic Therapeutics

Advance SEC workflows for genetic medicines. Discover wide-pore column technology for high-resolution characterization of mRNA, LNPs, and viral vectors

Advancing SEC for Characterization of Genetic Medicines

<h4><strong>How can you know that you catch all PFAS?</strong></h4><p><strong>Per- and polyfluoroalkyl substances (PFAS) comprise a group of highly persistent compounds that pose significant environmental concerns, particularly in water quality monitoring. Comprehensive characterization of PFAS contamination remains analytically challenging due to the chemical diversity of these substances and the limitations of individual methods.</strong></p><p>This webinar discusses complementary ion chromatography–based approaches for PFAS analysis in accordance with current standards. Combustion ion chromatography (CIC) enables the reliable determination of the total PFAS-related sum parameter AOF (adsorbable organically bound fluorine) and is standardized in DIN 38409-59, ISO 18127, and EPA 1621. &nbsp;This approach provides a robust overview of PFAS contamination levels.</p><p>However, the AOF approach does not capture all PFAS. Ultra-short chain PFAS are highly hydrophilic and are less efficiently retained on activated carbon, and therefore are not detected by AOF analysis. One of the most prominent ultra-short chain PFAS is trifluoroacetic acid (TFA), a relevant degradation product that may account for a significant proportion of total PFAS in water samples. Ion chromatography coupled with mass spectrometry (IC-MS/MS) provides a sensitive and reliable approach for TFA determination in water matrices. In this webinar, the validated approach in accordance with DIN 38407-53 will be presented.&nbsp;</p><h4><strong>Key learnings of this webinar:</strong></h4><ul><li>Understand the regulatory background for PFAS analysis in water (DIN 38409‑59, ISO 18127, EPA 1621, DIN 38407‑53)</li><li>Learn how combustion ion chromatography (CIC) enables the reliable determination of total PFAS-related parameters such as AOF</li><li>Understand the relevance of trifluoroacetic acid (TFA) as a key ultra-short chain PFAS in water quality monitoring</li><li>Discover how IC‑MS/MS provides a sensitive and reliable approach for TFA determination according to DIN 38407‑53</li></ul><h4><strong>Who should attend?</strong></h4><ul><li>Water utility operators who need robust and dependable analytical techniques to guarantee the safety of drinking water</li><li>Scientists, researchers, and analytical method developers who need to stay up -to date on sophisticated/state-of-the-art methods for water analysis</li><li>Laboratory staff and managers who considering implementing reliable, cost- and time-efficient analysis of HAA in their lab</li></ul><blockquote><p><strong>Speaker: </strong>Dr. Katinka Ruth (Senior Application Specialist IC, Metrohm International Headquarters)</p><p>Dr. Ruth received her MSc in Chemistry at the Technical University Munich and a PhD in Environmental Sciences at the Swiss Federal Institute of Technology (ETH Zurich). She gained extensive knowledge in ion chromatography and hyphenation of ion chromatography to mass spectrometers during her 17 years of experience at Metrohm International Headquarters, where she holds a position as Senior Application Specialist.</p></blockquote><blockquote><p><strong>Speaker:&nbsp;</strong>Theresa Steurer (Product Specialist IC, Metrohm International Headquarters)</p><p>Theresa Steurer is a Product Specialist in the Ion Chromatography Competence Center at Metrohm International Headquarters in Herisau, Switzerland. She holds a degree in chemistry from the University of Vienna.</p><p>With over eight years of experience in the ion chromatography applications laboratory, Theresa has developed extensive expertise in ion chromatography, with a particular focus on combustion ion chromatography.</p></blockquote>

Metrohm: PFAS Analysis with Ion Chromatography-Based Techniques

From Challenge to Confidence: PFAS Analysis with Ion Chromatography-Based Techniques

Advance your PFAS water monitoring. Combine Combustion IC for total AOF determination with IC-MS/MS for sensitive ultra-short chain TFA quantification

How to Ensure Complete PFAS Detection in Water Analysis

<p><strong>Robustness, reproducibility, and scalability are becoming increasingly important as proteomics workflows move closer to clinical and diagnostic applications.</strong></p><p>In this webinar, we will explore how the Evosep Eno supports the development of robust diagnostic assays through standardized, high-throughput LC–MS workflows. Join us to learn how reproducible performance, streamlined operation, and scalable proteomics methods can help accelerate the transition from discovery research to real-world applications.</p><h5><strong>Robust Data from Evosep Eno coupled to Exploris 480 for the Development of Diagnostic Assays</strong></h5><p>Models derived from machine learning approaches possess enormous diagnostic potential. At OXcan we create reliable machine learning models using training data sets generated from LC-MS data. A good model is accurate, reliable, and resistant to overfitting. In order to achieve this performance, the clinical and control data must have enough features and be sufficiently robust to allow the model to generate diagnostic features with a high degree of confidence.</p><p>Accepting that there is a pressing need to create reliable proteomic data, to facilitate the training of machine learning models, we will discuss our workflow for generating robust data from digested plasma samples. The workflow leverages the performance capabilities of our Evosep Eno LC system coupled to a Thermo Exploris MS. This LC-MS platform gives us reproducible data, with the throughput required for the development of our machine learning derived diagnostic assays.</p><blockquote><p><strong>Speaker:</strong> Giles Drinkwater (Researcher at OXcan Analytics)</p></blockquote>

Evosep: Assay Development for translational and research applications

Assay Development for translational and research applications

Advance translational proteomics for diagnostic assays. Explore high-throughput LC-MS workflows using Evosep Eno and Exploris 480 for machine learning models

High-Throughput LC-MS Workflows for Diagnostic Assays

<p><strong>Effective gene therapies require a thorough understanding of your delivery vehicle. Is it the right size? Does it contain an intact capsid, payload, and surface markers? Classic characterization methods don’t give structural insights, only look for a single component, and require purified samples to get actionable results. With the rise of in vivo CAR-T cell therapies, viral vectors have become increasingly complex to target the right cells and deliver cargo at the right time. Researchers need flexibility to adapt their characterization to the rapidly changing strategies for specified cell targeting and efficient gene delivery.</strong></p><p>Leprechaun is the only platform to deliver the complete biophysical ins and outs of individual lentivirus particles, with any combination of surface markers, at any stage from cell harvest to final stage, purified. Leprechaun combines interferometry and multi-channel fluorescence using a maximum of 25 µL of lentivirus, to characterize up to 16 samples in as little as a few hours. By assessing quality of lenti preps earlier in development, Leprechaun helps researchers obtain the most structurally intact lentivirus.</p><p>In this webinar, we'll cover how Leprechaun delivers both sizing and structural data on lentivirus particles throughout purification and pinpoint steps for optimization. We’ll show how Leprechaun goes beyond ELISA and qPCR to provide additional insights by measuring multiple parameters on the same sample. Additionally, we’ll show some unique assays to measure breakout CAR expression to make sure your lenti is ready for in vivo CAR-T action. All these results showcase how Leprechaun is the go-to tool for complete biophysical characterization of lenti being developed for in vivo CAR-T cell therapies.<br>&nbsp;</p><blockquote><p><strong>Presenter:&nbsp;</strong>Brian Haldeman<strong> </strong>(Product Manager, Leprechaun, Unchained Labs)</p></blockquote>

Unchained Labs: Know the ins and outs of your lentivirus with Leprechaun 

Know the ins and outs of your lentivirus with Leprechaun

Characterize lentivirus particles for in vivo CAR-T cell therapies. Learn how Leprechaun delivers biophysical insights on sizing and surface markers

Advanced Lentivirus Characterization with Leprechaun

<p><strong>In a high-volume seized drug laboratory, identifying a robust and efficient case workflow is crucial for achieving high case throughput. It is imperative to balance multiple key factors to ensure an efficient workflow for successful presumptive testing of seized drug cases, including method speed (analytical time), analyst involvement, a comprehensive database, and ease of use. The upcoming webinar will address how the Acquity UPLC with the RDa detector has been employed to develop a comprehensive and efficient workflow for screening seized drug cases that incorporates all of the key factors.</strong></p><blockquote><p><strong>Presenter: </strong>Dr. Erin Shonsey (Director of Research and Development, Alabama Department of Forensic Sciences)</p><p>Dr. Erin Shonsey is the Director of Research and Development for the Alabama Department of Forensic Sciences. As a board certified fellow of the American Board of Criminalistics in Drug Analysis, Dr. Shonsey received her Bachelor’s degree in Chemistry from Creighton University and her PhD in Pharmacology and Toxicology from the University of Alabama at Birmingham. With 15 years of experience, Dr. Shonsey provides technical oversight in the development and implementation of methodology for analysis of new and emerging drugs. Her keen ability to efficiently tackle this constant cat and mouse game has positioned Alabama’s only forensic crime laboratory to be able to identify the constant influx of drugs plaguing every community in Alabama.</p></blockquote>

Waters Corporation: Next-gen HRMS for toxicology and drug labs

Development and Implementation of an Efficient LC-TOF MS Screening Workflow in Seized Drug Analysis

The upcoming webinar will address how the Acquity UPLC with the RDa detector has been employed to develop a workflow for screening seized drug cases.

Related content

Benchmarking Lysosome Enrichment Methods: A Guide for Research and Clinical Translation

Webinars LabRulezLCMS Week 25/2026

How GLP-1 Drugs Are Analyzed: Chromatography & Mass Spectrometry Explained